Prevalence of Antiphospholipid Antibodies in Ankylosing Spondylitis: A Study of 80 Patients
试验速览
- 阶段
- 不适用
- 发起方
- CHU de Reims
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- presence or absence of APLA
研究概览
简要总结
The main objective is to evaluate the prevalence of anti-phospholipid antibodies (APLA) in patients with ankylosing spondylitis (AS).
The secondary objectives are: (1) To determine whether the presence of these antibodies is symptomatic (thrombosis or not); (2) Identify a possible relationship between the presence of APLA and a particular form of SA (axial or peripheral); (3) To determine whether the presence of APLA is more frequent in patients receiving anti-tumor necrosis factor (TNF) alpha therapy.
详细描述
Methods:
Experimental design: longitudinal study prospective in a single center.
The Ankylosing Spondylitis Assesment Study (ASAS) criteria are: (1) age <45 years, back pain ≥ 3 months, sacroiliitis on imaging and ≥ 1 associated minor criterion, or (2) HLA B27 positive and ≥ 2 minor criteria.
Minor criteria are: inflammatory back pain, arthritis, enthesitis, uveitis, Dactylitis, psoriasis, Crohn's disease, good clinical response to NSAIDs, family history of Human Leukocyte Antigen HLA B27 and inflammatory syndrome.
Plan Investigation:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •older than 18 years
- •with SA according to ASAS criteria
- •followed in the Internal Medicine Department of the REIMS University Hospital
- •who have given their consent
- •affiliated to social security insurance
排除标准
- •minor patients
- •patients with autoimmune disease (except the inflammatory bowel disease)
- •coagulation disorders
- •anticoagulant treatment (anticoagulation out for events history thrombus embolism)
- •pregnant women
- •patients protected by law
研究组 & 干预措施
ankylosing spondylarthritis
干预措施: blood collection (Biological)
结局指标
主要结局
presence or absence of APLA
时间窗: 12 weeks
次要结局
未报告次要终点